Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Menyanthes Trifoliata is a botanical substance primarily utilized in clinical settings as a non-standardized plant allergenic extract for the diagnosis and treatment of hypersensitivity. It belongs to the class of Non-Standardized Plant Allergenic Extracts [EPC].
Name
Menyanthes Trifoliata
Raw Name
MENYANTHES TRIFOLIATA
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
4
Variant Count
4
Last Verified
February 17, 2026
About Menyanthes Trifoliata
Menyanthes Trifoliata is a botanical substance primarily utilized in clinical settings as a non-standardized plant allergenic extract for the diagnosis and treatment of hypersensitivity. It belongs to the class of Non-Standardized Plant Allergenic Extracts [EPC].
Detailed information about Menyanthes Trifoliata
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Menyanthes Trifoliata.
Menyanthes Trifoliata, commonly known as bogbean or buckbean, is a perennial aquatic plant belonging to the family Menyanthaceae. In the contemporary clinical landscape of 2026, Menyanthes Trifoliata is primarily recognized and regulated as a Non-Standardized Plant Allergenic Extract [EPC]. This pharmacological classification places it within a group of substances used by allergists and immunologists to diagnose and treat specific allergic sensitivities. Unlike standardized extracts, which have a defined potency measured by bioequivalent units, non-standardized extracts like Menyanthes Trifoliata are prepared using traditional weight-to-volume (w/v) ratios or Protein Nitrogen Unit (PNU) measurements.
Historically, the plant was utilized in traditional European medicine as a 'bitter tonic' to stimulate digestion, but its modern medical application is strictly controlled under the FDA's Center for Biologics Evaluation and Research (CBER). The extract is derived from the dried leaves of the plant and is processed into a sterile solution for parenteral (injectable) administration. As a member of the non-standardized plant allergenic extract class, it is used to identify patients who have developed IgE-mediated hypersensitivity to the proteins found within the bogbean plant, which may be relevant for individuals with occupational exposure or those living in specific boggy or wetland ecosystems where the plant is prevalent.
The mechanism of action for Menyanthes Trifoliata, when used as an allergenic extract, is rooted in the fundamental principles of immunology. At the molecular level, the extract contains a complex mixture of proteins, glycoproteins, and polysaccharides derived from the plant's cellular structure. When introduced into the skin of a sensitized individual—either through a skin prick test (percutaneous) or an intradermal injection—these allergenic proteins encounter specific Immunoglobulin E (IgE) antibodies that are bound to the surface of mast cells and basophils.
If the patient is sensitized, the Menyanthes Trifoliata allergens cross-link the IgE molecules, triggering a cascade of intracellular signaling. This leads to the degranulation of mast cells, resulting in the release of inflammatory mediators such as histamine, leukotrienes, and prostaglandins. This localized reaction manifests as a 'wheal and flare' (a raised bump surrounded by redness), which allows the healthcare provider to confirm the presence of a Type I hypersensitivity. In the context of immunotherapy (allergy shots), the repeated, controlled administration of the extract is thought to shift the immune response from a Th2-dominated (allergic) profile to a Th1-dominated or regulatory T-cell (Treg) profile, eventually inducing desensitization or clinical tolerance.
According to current clinical protocols, Menyanthes Trifoliata allergenic extract is indicated for:
Menyanthes Trifoliata is typically available in the following forms:
> Important: Only your healthcare provider can determine if Menyanthes Trifoliata is right for your specific condition. The use of allergenic extracts must be conducted under the supervision of a physician trained in the management of anaphylaxis.
Dosage for Menyanthes Trifoliata allergenic extract is highly individualized and must be determined by a qualified allergist. There is no 'standard' dose, as the concentration is adjusted based on the patient's sensitivity levels.
Menyanthes Trifoliata extract may be used in children; however, the starting dose is often even more conservative than in adults. Pediatric patients are at a higher risk for systemic reactions if the dose is escalated too quickly. Clinical guidelines suggest that immunotherapy should generally not be initiated in children under the age of 5 due to the difficulty of communicating early symptoms of a systemic reaction.
No specific dosage adjustments are typically required for patients with renal impairment, as the protein load is negligible. However, the patient's overall health should be considered before initiating immunotherapy.
No adjustments are necessary for hepatic impairment, as the liver does not play a primary role in the clearance of injected allergenic proteins.
Elderly patients require careful assessment of their cardiovascular status. If an older adult is taking beta-blockers or ACE inhibitors for hypertension, the risk of a severe, treatment-resistant reaction to the extract is significantly increased.
Menyanthes Trifoliata extract is never self-administered by the patient at home. It must be administered in a clinical setting equipped with emergency resuscitation equipment.
If a dose of immunotherapy is missed, the next dose may need to be reduced depending on how much time has passed.
An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level, leading to a systemic reaction. Signs include generalized itching, hives, swelling of the throat, wheezing, and a drop in blood pressure. Emergency treatment with epinephrine (Adrenalin) is required immediately.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Never attempt to administer this medication outside of a medical facility.
The most frequent side effects associated with Menyanthes Trifoliata are localized to the site of administration. These are often expected and indicate that the immune system is responding to the allergen.
> Warning: Stop taking Menyanthes Trifoliata and call your doctor immediately if you experience any of these symptoms of anaphylaxis.
With prolonged immunotherapy use, the primary long-term effect is the intended desensitization. However, some patients may develop a persistent 'late-phase' reaction where they experience localized swelling more frequently. There is no evidence that Menyanthes Trifoliata causes organ damage or increases the risk of cancer over long-term use.
According to the FDA-standardized labeling for allergenic extracts (which includes Menyanthes Trifoliata):
Report any unusual symptoms to your healthcare provider immediately. Even a mild reaction today could predict a more severe reaction in the future.
Menyanthes Trifoliata is a potent biological substance. Its safety is entirely dependent on proper administration and patient selection. Patients must be transparent with their healthcare providers regarding their current health status, especially any history of asthma or heart disease.
No specific unique black box warning exists for Menyanthes Trifoliata beyond the standard class-wide warning for all non-standardized allergenic extracts. This warning emphasizes the risk of anaphylaxis and the necessity of administration in a controlled medical environment by trained personnel.
While taking Menyanthes Trifoliata for immunotherapy, the following monitoring is required:
Most patients can drive after their 30-minute observation period. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive and must be monitored further.
Alcohol consumption should be avoided on the day of an immunotherapy injection. Alcohol can increase peripheral vasodilation, which may potentially accelerate the absorption of the allergen or exacerbate the symptoms of a systemic reaction.
If a patient experiences repeated systemic reactions despite dose adjustments, the healthcare provider may decide to discontinue Menyanthes Trifoliata immunotherapy. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the patient's allergy symptoms will likely return to their baseline over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Menyanthes Trifoliata.
There are few absolute contraindications for drug combinations, but the following are considered extremely high-risk:
There are no direct food-drug interactions with Menyanthes Trifoliata. However, patients should avoid eating a heavy meal or consuming very hot beverages immediately before or after an injection, as these can increase core body temperature and blood flow, potentially affecting allergen absorption.
For each major interaction, the primary concern is not the degradation of the Menyanthes Trifoliata extract, but rather the interference with the patient's physiological response to the allergen or the medical team's ability to treat a reaction.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Menyanthes Trifoliata must NEVER be used in the following circumstances:
These conditions require a careful risk-benefit analysis by the physician:
Patients who are highly allergic to other members of the Menyanthaceae family or certain related aquatic plants may show cross-reactivity. If a patient has had a severe reaction to a related plant extract, Menyanthes Trifoliata should be used with extreme caution.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Menyanthes Trifoliata.
Menyanthes Trifoliata is classified as FDA Pregnancy Category C. This means that animal reproduction studies have not been conducted, and it is not known whether the extract can cause fetal harm.
It is not known whether the allergenic proteins in Menyanthes Trifoliata pass into breast milk. However, because these are large proteins that are likely digested in the infant's gut, the risk to a nursing child is considered very low. The primary concern remains the mother's safety and the potential for a systemic reaction.
As noted, Menyanthes Trifoliata is used in children, but with caution. It is not recommended for children under 5 years of age. For older children, the dose must be carefully titrated, and the child must be able to cooperate with the injection and observation process.
Patients over the age of 65 are at increased risk for cardiovascular complications. Before starting Menyanthes Trifoliata, an EKG and a thorough review of cardiac medications (especially beta-blockers) are essential. The 'start low and go slow' approach is mandatory for this population.
No specific GFR-based adjustments are documented for Menyanthes Trifoliata. The proteins are not nephrotoxic, and the volume of the injection is too small to affect fluid balance.
There are no specific guidelines for hepatic impairment. The liver's metabolic capacity does not significantly impact the safety or efficacy of this allergenic extract.
> Important: Special populations require individualized medical assessment and a personalized treatment plan.
Menyanthes Trifoliata acts as an exogenous antigen. In diagnostic use, it facilitates the 'bridging' of surface-bound IgE on mast cells. In therapeutic use (immunotherapy), it induces a state of 'immunological tolerance.' This is achieved through several pathways:
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Intradermal) |
| Protein Binding | High (to IgE and IgG antibodies) |
| Half-life | Proteins: Minutes to Hours; Immunological effect: Years |
| Tmax | 15-30 minutes (for local reaction) |
| Metabolism | Proteolytic degradation |
| Excretion | Renal (as peptide fragments) |
Menyanthes Trifoliata extract is a complex biological mixture. It contains iridoid glycosides (such as loganin and sweroside), flavonoids, and various proteins. The molecular weight of the relevant allergenic proteins typically ranges from 10 kDa to 70 kDa. It is soluble in water and buffered saline solutions.
Menyanthes Trifoliata is a Non-Standardized Plant Allergenic Extract. It is grouped with other botanical allergens like ragweed, oak, and various grasses used in clinical allergy practice.
Medications containing this ingredient
Common questions about Menyanthes Trifoliata
Menyanthes Trifoliata is primarily used in clinical allergy medicine for two purposes: diagnosing a specific allergy to the bogbean plant and treating that allergy through immunotherapy. For diagnosis, a small amount of the extract is applied to the skin to see if a 'wheal and flare' reaction occurs, indicating the presence of IgE antibodies. For treatment, increasingly larger doses are injected over time to help the immune system become less sensitive to the plant. This process is typically reserved for patients whose symptoms are not well-controlled by standard medications. It is not used for general health supplementation in a clinical context.
The most common side effects are localized reactions at the site of the skin test or injection, which occur in a majority of patients. These include redness, itching, and a raised bump (wheal) that typically appears within 20 minutes and fades within an hour. Some patients may also experience 'delayed' local reactions, where the arm becomes swollen and warm several hours after the injection. While these local reactions can be uncomfortable, they are generally not dangerous. However, they must be reported to the doctor as they may influence the size of the next dose.
It is strongly advised that patients avoid alcohol on the days they receive a Menyanthes Trifoliata injection. Alcohol causes the blood vessels to dilate, which can potentially speed up the absorption of the allergen into the bloodstream, increasing the risk of a systemic reaction. Furthermore, alcohol can mask the early symptoms of an allergic reaction or make it more difficult for doctors to stabilize a patient's blood pressure if anaphylaxis occurs. For the highest level of safety, wait at least 24 hours after your injection before consuming alcohol. Always consult your healthcare provider for specific guidance based on your health history.
Menyanthes Trifoliata is generally not initiated during pregnancy due to the risk of systemic allergic reactions. If a pregnant woman has a severe reaction (anaphylaxis), it can cause a dangerous drop in blood pressure and oxygen levels, which can be harmful to the developing fetus. However, if a patient is already on a stable maintenance dose of immunotherapy before becoming pregnant, many allergists will continue the treatment while monitoring the patient closely. Decisions regarding the use of this extract during pregnancy are made on a case-by-case basis. You must inform your allergist immediately if you become pregnant or are planning to conceive.
When used for diagnostic skin testing, Menyanthes Trifoliata works almost immediately, with results visible within 15 to 20 minutes. However, when used for immunotherapy (allergy shots), the process is much slower. Most patients undergo a 'buildup phase' lasting 3 to 6 months, followed by a 'maintenance phase.' Significant improvement in allergy symptoms is typically not noticed until the patient has been on the maintenance dose for several months. A full course of treatment usually lasts 3 to 5 years to provide long-lasting relief. Patience and consistency are key to the success of this treatment.
Yes, you can stop taking Menyanthes Trifoliata injections at any time without experiencing physical withdrawal symptoms, as it is not an addictive substance. However, stopping the treatment before the recommended 3-to-5-year course is complete will likely result in the return of your original allergy symptoms. If you miss several doses, you cannot simply resume at your previous dose; your doctor will need to reduce the concentration to ensure your safety. Always discuss your reasons for wanting to stop with your allergist, as they may be able to adjust the schedule to better suit your needs.
If you miss a scheduled immunotherapy dose, you should contact your allergist's office as soon as possible to reschedule. The safety of the next dose depends on how much time has elapsed since your last injection. If you are only a few days late, the doctor may give you the usual dose. If several weeks have passed, the doctor will likely need to decrease the dose to prevent a systemic reaction, as your body's tolerance may have decreased. Never attempt to 'double up' on doses to make up for a missed one, as this significantly increases the risk of anaphylaxis.
There is no clinical evidence to suggest that Menyanthes Trifoliata allergenic extract causes weight gain. The extract consists of proteins and small amounts of preservatives, and it does not contain calories or hormones that would affect metabolism or appetite. If you experience weight changes while on immunotherapy, it is likely due to other factors, such as lifestyle changes or other medications (like oral corticosteroids) that you might be taking for your allergies. If you have concerns about weight gain, you should discuss them with your primary care physician to identify the underlying cause.
Menyanthes Trifoliata can be taken alongside many common medications, but certain drugs pose significant risks. The most concerning are beta-blockers and ACE inhibitors, which are used for heart conditions and high blood pressure. These medications can make a systemic allergic reaction much more severe and harder to treat with epinephrine. Antihistamines must be avoided before diagnostic testing because they will block the skin's reaction to the extract, leading to inaccurate results. Always provide your allergist with a complete and updated list of all medications, including over-the-counter drugs and herbal supplements, before each injection.
The concept of 'generic' vs. 'brand name' is slightly different for allergenic extracts compared to standard pills. Menyanthes Trifoliata is a biological product, and different laboratories may produce their own versions of the extract. These are generally considered 'non-standardized' products rather than generics. While different brands may be available, they are not necessarily interchangeable because the concentration of specific proteins can vary between manufacturers. Once you start treatment with a specific manufacturer's extract, your doctor will typically try to keep you on that same product to ensure consistent dosing and safety.